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Preterm birth is the most common cause of neonatal 
morbidity and mortality globally, aﬀ ecting about 
15 million children every year.1 Of children born preterm, 
an estimated 2·4 million (15·6%) are born extremely 
preterm (before 28 weeks gestation) or very preterm 
(before 32 weeks gestation).1 Furthermore, some 
1 million children every year die as a consequence of 
preterm birth or its complications.1 In 2014, the Preterm 
Birth Priority Setting Partnership in the UK identiﬁ ed 
prediction and prevention of preterm birth as the top 
research priority in this area.2
Progesterone has been considered a promising 
therapeutic agent to prevent preterm birth. Having 
been assessed in several small, randomised trials in the 
1960s and 1970s, a meta-analysis by Keirse3 identiﬁ ed 
a reduction in the occurrence of preterm birth after 
antenatal use of progesterone. This ﬁ nding inspired 
others to undertake new randomised trials, and in 
2003, both Meis and colleagues4 and Da Fonseca and 
colleagues5 reported a reduction of preterm birth in 
women with previous preterm birth after treatment 
with 17α-hydroxyprogesterone caproate and vaginal 
progesterone, respectively. Subsequent meta-analysis 
(incorporating both intramuscular and vaginal 
preparations) conﬁ rmed that progestogens could prolong 
pregnancy, and were associated with a reduction in short-
term neonatal mortality and morbidity.6 However, it 
remains uncertain whether this approach is associated 
with improvements in long-term outcomes for children. 
Whereas longer duration of pregnancy is often related to 
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long as most of us remember. Its eﬃ  cacy has never been 
properly established or quantiﬁ ed in chronic diseases, 
and is probably not as great as many would believe. 
Its safety is also questioned,9 not just in overdose.10 Is 
recommending it as the universal ﬁ rst-line analgesic in 
osteoarthritis still tenable?
Many patients could be suﬀ ering needlessly because of 
perceived NSAIDs risks and paracetamol beneﬁ ts (which 
might not be real). Perhaps researchers need to reassess 
both these perceptions (or misconceptions) and the 
use of other analgesic options that have been discarded 
over time, such as dipyrone. Certainly, opioids are not 
a good solution for benign pain. Chondroitin sulphate 
or glucosamine might not be very eﬀ ective either11 but 
could be safer than paracetamol or opioids. Other herbal 
preparations might also warrant scrutiny.12
A crucial need remains to ﬁ nd new painkillers for 
osteoarthritis. Have any new analgesics been released 
since ibuprofen and diclofenac came out in the early 1970s, 
apart from the clinically minor COX-2 selective NSAIDs? All 
existing painkillers are merely minor variations on those 
early NSAIDs or opioids. Can’t we do better?
*Nicholas Moore, Francesco Salvo, Mai Duong, 
Sinem Ezgi Gulmez
Bordeaux Pharmacoepi, Department of Pharmacology, INSERM 
U657, CIC1401, University of Bordeaux, 33076 Bordeaux, France
nicholas.moore@u-bordeaux.fr
NM would like to thank his research team, who over the years has let him pursue the 
topic of low-dose NSAIDs. NM has received grants for studies at the University of 
Bordeaux and personal fees for work related to non-steroidal anti-inﬂ ammatory 
drugs and paracetamol from Boots, Reckitt-Benckiser, Novartis, Pﬁ zer, Roche, Rhone 
Poulenc, Sanoﬁ , and Helsinn. All other authors declare no competing interests.
1 da Costa BR, Reichenbach S, Keller N, et al. Eﬀ ectiveness of non-steroidal 
anti-inﬂ ammatory drugs for the treatment of pain in knee and hip 
osteoarthritis: a network meta-analysis. Lancet 2015; published online 
March 17. http://dx.doi.org/10.1016/S0140-6736(16)30002-2.
2 Riendeau D, Percival MD, Brideau C, et al. Etoricoxib (MK-0663): 
preclinical proﬁ le and comparison with other agents that selectively inhibit 
cyclooxygenase-2. J Pharmacol Exp Ther 2001; 296: 558–66.
3 Kellner HL, Li C, Essex MN. Eﬃ  cacy and safety of celecoxib versus diclofenac 
and omeprazole in elderly arthritis patients: a subgroup analysis of the 
CONDOR trial. Curr Med Res Opin 2012; 28: 1537–45.
4 Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal 
toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. 
VIGOR Study Group. N Engl J Med 2000; 343: 1520–28.
5 Moore N, Diris H, Martin K, et al. NSAID use proﬁ les derived from 
reimbursement data in France. Therapie 2004; 59: 541–46.
6 Duong M, Salvo F, Pariente A, et al. Usage patterns of ‘over-the-counter’ 
vs. prescription-strength nonsteroidal anti-inﬂ ammatory drugs in France. 
Br J Clin Pharmacol 2014; 77: 887–95.
7 Moore N, Van Ganse E, Le Parc J, et al. The PAIN study: Paracetamol, 
Aspirin and Ibuprofen New tolerability study. A large scale, randomized 
clinical trial comparing the tolerability of aspirin, ibuprofen and 
paracetamol for short-term analgesia. Clin Drug Invest 1999; 18: 89–98.
8 Laharie D, Droz-Perroteau C, Benichou J, et al. Hospitalizations for 
gastrointestinal and cardiovascular events in the CADEUS cohort of 
traditional or coxib NSAID users. Br J Clin Pharmacol 2010; 69: 295–302.
9 Roberts E, Delgado Nunes V, Buckner S, et al. Paracetamol: not as safe as we 
thought? A systematic literature review of observational studies. 
Ann Rheum Dis 2015; 75: 552–59.
10 Gulmez SE, Larrey D, Pageaux GP, et al. Transplantation for acute liver 
failure in patients exposed to NSAIDs or paracetamol (acetaminophen): 
the multinational case-population SALT study. Drug Saf 2013; 36: 135–44.
11 Sawitzke AD, Shi H, Finco MF, et al. Clinical eﬃ  cacy and safety of 
glucosamine, chondroitin sulphate, their combination, celecoxib or 
placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. 
Ann Rheum Dis 2010; 69: 1459–64.
12 Cameron M, Chrubasik S. Oral herbal therapies for treating osteoarthritis. 
Cochrane Database Syst Rev 2014; 5: CD002947. 
Published Online
February 23, 2016
http://dx.doi.org/10.1016/
S0140-6736(16)00543-2
See Articles page 2106
Progesterone
La
gu
na
 D
es
ig
n/
Sc
ie
nc
e 
Ph
ot
o 
Li
br
ar
y 
Comment
www.thelancet.com   Vol 387   May 21, 2016 2067
better neonatal outcomes, a longer stay in a hazardous 
uterine environment might be harmful.7
In The Lancet, Jane Norman and colleagues8 report 
the eﬀ ect of vaginal progesterone (200 mg daily 
taken from 22–24 to 34 weeks of gestation) in 
1228 women at increased risk for preterm birth on 
early child development at 2 years of age. They did a 
randomised, multicentre, placebo-controlled study 
using rigorous standards, including an assessment of 
maternal compliance with medication, an unbiased 
assessment of outcomes, and used a sample size larger 
than all of the previously published studies combined. The 
authors report three primary family-centred outcomes, 
an obstetric outcome (fetal death or delivery before 
34 weeks and 0 days of gestation), a neonatal outcome 
(composite of death, bronchopulmonary dysplasia, 
and brain injury), and a childhood outcome (Bayley-III 
cognitive composite score), reﬂ ecting the fact that the 
eﬀ ect of the intervention is through the prolongation 
of pregnancy, with an anticipated beneﬁ t in improved 
neonatal and child health. Progesterone had no 
signiﬁ cant eﬀ ect on the primary obstetric outcome (odds 
ratio adjusted for multiple comparisons [OR] 0·86, 95% CI 
0·61–1·22) or neonatal outcome (OR 0·62, 0·38–1·03).
Although the OPPTIMUM study itself shows no 
diﬀ erence on the primary obstetric and neonatal 
outcome, all obstetric and neonatal outcomes showed 
a reduction in the occurrence of unwanted neonatal 
outcomes after the administration of progesterone 
(neonatal death, unadjusted OR 0·17, 95% CI 
0·06–0·49; brain injury on ultrasound 0·50, 0·31–0·84). 
However, there was no identiﬁ able improvement in 
child development when assessed at 2 years of age 
(cognitive score, progesterone group vs placebo group, 
97·3 [SD 17·9] vs 97·7 [17·5]; diﬀ erence in means –0·48, 
95% CI –2·77 to 1·81). It will be important to incorporate 
these ﬁ ndings into subsequent updates of the Cochrane 
Systematic Reviews on this topic.
First, the results from OPPTIMUM highlight the 
importance of perinatal trials to routinely follow up 
maternal and child participants after birth. As shown 
by Norman and colleagues, the risk–beneﬁ t ratio of 
any perinatal intervention might vary considerably 
according to eﬀ ects on the woman and her infant, both 
immediately after birth and extending into childhood, 
as has been shown with the use of antibiotics for 
women in spontaneous preterm labour, or the eﬀ ects 
of multiple doses of corticosteroids.9,10 It could be 
assumed that when an intervention does not inﬂ uence 
the mechanism it aims to improve—for example 
prolongation of pregnancy—it does not work. However, 
the opposite is not guaranteed: successful short-term 
improvements in health do not necessarily correlate 
with improvements in longer-term health outcomes. 
Although this might be a message that complicates 
the lives not only of researchers, but also of research 
funders, it is an important reality. Researchers should 
consider the long-term eﬀ ects for both neonates and 
their families; every study of a perinatal intervention 
that shows short-term beneﬁ ts should ideally include 
longer-term follow-up of participants to assess potential 
beneﬁ ts and harms.
Second, careful consideration of the interpretation 
of the 2-year outcome is needed. It is interesting that 
the better neonatal outcome of vaginal progesterone 
does not translate to any beneﬁ t in terms of longer-
term child health. Although there might be associations 
between short-term morbidity and longer-term 
health, the lack of observed eﬀ ect could reﬂ ect both 
the impact of a multitude of postnatal factors (eg, 
socioeconomic factors, attention to the child) on child 
development, as well as the relative imprecision of the 
Bayley-III cognitive scale, meaning that more subtle 
developmental variations might go undetected.11
Third, since OPPTIMUM also indicates that at 2 years 
of age no harm is to be anticipated from progesterone, 
the decision to use progesterone or not also becomes 
an issue of shared decision making. The most important 
short-term perinatal outcome for preterm birth, 
neonatal death, occurred in one of the children in the 
progesterone group compared with six in the placebo 
group (unadjusted OR 0·17, 95% CI 0·06–0·49). Similarly, 
a meta-analysis had already indicated that progesterone 
reduced the risk of perinatal mortality in women with a 
history of spontaneous preterm birth (risk ratio [RR] 0·50, 
95% CI 0·33–0·75) and in women with an ultrasound-
identiﬁed short cervix (RR 0·74, 95% CI 0·42–1·29).6 
Obviously, for parents who have suﬀ ered the loss of a 
child due to prematurity the decision to use progesterone 
in a subsequent pregnancy might be inﬂ uenced by this 
information. This decision should be weighed against the 
fact that in Norman and colleagues’ study8 the diﬀ erence 
in neonatal death rate was not seen in the death rate at 
the age of 2 years (hazard ratio 1·28, 95% CI 0·66–2·51). 
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With 15 million premature babies born worldwide 
every year, premature birth is the biggest problem in 
obstetrics.1 It is not only the most common reason that 
newborn babies die,1 but is also an important cause 
of long-term brain, bowel, lung, and eye damage. 
Antenatal steroids reduce the risk of lung disease, 
intracranial bleeding, and death2 and magnesium 
sulphate reduces cerebral palsy.3 Obstetricians often also 
prescribe uterine relaxant, or tocolytic, drugs to delay 
birth, albeit without much evidence to support this 
practice. Current policy4,5 is generally to limit tocolysis 
to 48 h to gain the maximum beneﬁ t from steroids 
and allow in-utero transfer to a suitable intensive-care 
facility. But which tocolytic should be used? 
Five drug groups have been tried. β adrenoceptor 
agonists and cyclooxygenase inhibitors have been all 
but abandoned due to side-eﬀ ects and magnesium 
sulphate, although neuroprotective, is an ineﬀ ective 
tocolytic.6 Only calcium-channel blockers, of which 
nifedipine is the most widely studied, and the oxytocin 
antagonist atosiban remain in widespread use. Three 
direct comparison trials have been done but were small7–9 
and two were unregistered.7,8 Eﬀ orts to compare the two 
drugs by indirect10 or network meta-analyses11 have been 
unconvincing because of the variable methodological 
quality of the component trials. Nevertheless, most 
international guidelines (apart from those in the USA 
where atosiban is unavailable) currently recommend 
one of these drugs as ﬁ rst-line tocolytic drugs.4,5
In The Lancet, Elvira van Vliet and colleagues12 present 
ﬁ ndings from APOSTEL III, a large, multicentre, 
randomised trial to compare perinatal outcomes after 
48 h of tocolysis with nifedipine versus atosiban in 
510 women with threatened preterm birth (25–34 weeks 
of gestation). 254 women were randomly assigned to oral 
nifedipine and 256 women to intravenous atosiban, with 
Tocolysis and preterm labour
Future use of standardised outcomes can prevent the 
variety of outcomes that have been used in the studies 
done thus far,12 and individual patient data meta-analysis 
of progestogens to prevent preterm birth will allow a 
better assessment of treatment beneﬁ ts, particularly 
for subgroups of women. The OPPTIMUM study is a 
step forward in the understanding of progesterone as a 
treatment in women at risk for preterm birth. The study 
also highlights the importance for perinatal trialists to 
incorporate at the outset an undertaking to continue 
to assess longer-term outcomes, to use standardised 
outcomes, and to integrate the obtained results. This 
can best be achieved in a global collaboration of those 
working on this topic.
*Ben W J Mol, Mandy Daly, Jodie M Dodd
The Robinson Research Institute, School of Paediatrics and 
Reproductive Health, University of Adelaide and The South 
Australian Health and Medical Research Institute, Adelaide, 
5000 SA, Australia (BWJM, JMD); The South Australian Health and 
Medical Research Institute, Adelaide, Australia (BWJM); and Irish 
Neonatal Health Alliance, Bray, County Wicklow, Ireland (MD)
ben.mol@adelaide.edu.au
BWJM is a member of the advisory board of ObsEva, Switzerland, and payments 
from this role go to his institute. MD and JMD declare no competing interests.
Copyright © Mol et al. Open Access article distributed under the terms of CC BY.
1 Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, and 
worldwide estimates of preterm birth rates in the year 2010 with time trends 
since 1990 for selected countries: a systematic analysis and implications. 
Lancet 2012; 379: 2162–72.
2 Duley L, Uhm S, Oliver S. Top 15 UK research priorities for preterm birth, on 
behalf of the Preterm Birth Priority Setting Partnership Steering Group. 
Lancet 2014; 383: 2041–42.
3 Keirse MJ. Progestogen administration in pregnancy may prevent preterm 
delivery. Br J Obstet Gynaecol 1990; 97: 149–54.
4 Meis PJ, Klebanoﬀ  M, Thom E, et al; National Institute of Child Health and 
Human Development Maternal-Fetal Medicine Units Network. Prevention of 
recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. 
N Engl J Med 2003; 348: 2379–85.
5 Da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic 
administration of progesterone by vaginal suppository to reduce the 
incidence of spontaneous preterm birth in women at increased risk: 
a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 
2003; 188: 419–24.
6 Dodd JM, Jones L, Flenady V, Cincotta R, Crowther CA. Prenatal administration 
of progesterone for preventing preterm birth in women considered to be at 
risk of preterm birth. Cochrane Database Systemat Rev 2013; 7: CD004947.
7 Alﬁ revic Z. Tocolytics: do they actually work? BMJ 2012; 345: e6531.
8 Norman JE, Marlow N, Messow C-M, et al, for the OPPTIMUM study group. 
Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): 
a multicentre, randomised, double-blind trial. Lancet 2016; published online 
Feb 23. http://dx.doi.org/10.1016/S0140-6736(16)00350-0.
9 Kenyon S, Pike K, Jones DR, et al. Childhood outcomes after prescription of 
antibiotics to pregnant women with spontaneous preterm labour: 7-year 
follow-up of the ORACLE II trial. Lancet 2008; 372: 1319–27.
10 Wapner RJ, Sorokin Y, Mele L, et al. Long-term outcomes after repeat doses of 
antenatal corticosteroids. N Engl J Med 2007; 357: 1190–98.
11 Anderson PJ, De Luca CR, Hutchinson E, Roberts G, Doyle LW, Victorian Infant 
Collaborative Group. Underestimation of developmental delay by the new 
Bayley-III scale. Arch Pediatr Adolesc Med 2010; 164: 352–56.
12 van ‘t Hooft J, Duﬀ y JM, Daly M, et al; Global Obstetrics Network (GONet). 
A core outcome set for evaluation of interventions to prevent preterm birth. 
Obstet Gynecol 2016; 127: 49–58.
Published Online
March 1, 2016
http://dx.doi.org/10.1016/
S0140-6736(16)00590-0
See Articles page 2117
